We observed a dose-dependent increase in annexin V-positive cells in these RAS- mutated MM cell lines after treatment with each inhibitor (P < 0.01 in each tipifarnib treatment doses versus control groups in each cell lines; P < 0.05 in AZD6244 treatment doses versus control groups in each cell lines; P < 0.05 in 5, 10, and 20 μM dabrafenib treatment doses versus control groups in NCI-H929 and MM.1S cells) (Fig 3C). This evidence concerns the gene ANXA5 and Miyoshi myopathy.